Omnigen® kit
Information for clinicians
What is the Omnigen kit?
Omnigen (Tereo-processed amniotic membrane) supports healing, limits inflammation progression, and reduces pain and discomfort by its physical presence for patients with ocular disorders. It can be efficiently delivered in an outpatient setting using OmniLenz, a specialised bandage contact lens. The insertion procedure for Omnigen using OmniLenz takes just 4 to 6 minutes.
Applied as an onlay-graft (patch), Omnigen sits over the damaged area like a biological bandage for the duration of treatment.
The Omnigen Kit has been specially designed to support healthcare professionals in applying Omnigen alongside OmniLenz. The kit contains all the required tools in a single package for easy outpatient application, including:
- Omnigen – Tereo processed amniotic membrane
- OmniLenz – Specially designed bandage contact lens
- Forceps
- Gallipot
- Spongy spears
Benefits of the Omnigen Kit
- Deploy an effective treatment to support ocular surface stabilisation in-clinic
- Apply Omnigen (amniotic membrane) in the outpatient setting in a quick 4 to 6-minute procedure
- Avoid issues with ordering additional consumables
- Expand your clinic treatment catalogue
- Simple, on-the-shelf treatment that is ready to go when you are
How to apply Omnigen with OmniLenz
Omnigen can be applied to the ocular surface using OmniLenz in a 4-6-minute procedure.
Information on the Omnigen kit
Availability of the Omnigen Kit
The Omnigen Kit is available to private hospitals and optical practices in the UK. Please note that the Omnigen Kit is not currently available for NHS hospitals or in countries outside of the UK.
Market Feedback and Post-Market Surveillance
The Omnigen Kit is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) as a procedure pack. Consequently, NuVision conducts bi-annual (six-monthly) surveys to gather Market Feedback from Omnigen users. This feedback enables NuVision to evaluate product usability, identify opportunities for continuous improvement, and inform future developments.
Additionally, all Omnigen orders include a post-market surveillance form. Provided in two parts, Part A to be completed upon treatment application and Part B at post-treatment follow-up. This form allows us to capture clinical outcomes and track real-world results across our patient cohort.
Incident Reporting and the Yellow Card Scheme
Any adverse incident or reaction should be reported directly to NuVision using our incident report form, or by contacting our Quality and Regulatory team at incident@nu-vision.co.uk or +44 (0)115 784 0120.
Patients and users can report any issues experienced with the Omnigen Kit directly through the MHRA Yellow Card scheme. A patient information card is included within each Omnigen Kit to pass on to your patient.
Further information can be found at yellowcard.mhra.gov.uk.
Want to know more?
Contact NuVision to be put in touch with your local account manager.